The clear benefits of implantable cardioverter-defibrillators (ICDs) in selected populations have been consistently demonstrated through landmark investigations for more than 2 decades.1 After initially demonstrating efficacy in secondary prophylaxis of sudden cardiac death (SCD),2 ICDs are now first-line therapy for primary prophylaxis of SCD in many patients with ischemic or nonischemic cardiomyopathy.3,4
Goldberger ZD, Fagerlin A. ICDs—Increasingly Complex DecisionsComment on “Patient Preference in the Decision to Place Implantable Cardioverter-Defibrillators”. Arch Intern Med. 2012;172(14):1106–1107. doi:10.1001/archinternmed.2012.2660
Customize your JAMA Network experience by selecting one or more topics from the list below.